Yoon SS - Search Results

1

Efficacy and Safety of Bispecific T-Cell Engagers in Relapsed/Refractory Multiple Myeloma: A Real-World Data-Based Case-Controlled Study.

Choi S, Byun JM, Park SS, Han J, Oh S, Jung S, Park H, Han S, Lee JY, Koh Y, Jeon YW, Yahng SA, Shin SH, Yoon SS, Min CK. Choi S, et al. Among authors: yoon ss. Transplant Cell Ther. 2024 Nov 26:S2666-6367(24)00779-6. doi: 10.1016/j.jtct.2024.11.010. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39608453

2

A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma.

Bang SM, Lee JH, Yoon SS, Park S, Min CK, Kim CC, Suh C, Sohn SK, Min YH, Lee JJ, Kim K, Seong CM, Yoon HJ, Cho KS, Jo DY, Lee KH, Lee NR, Kim CS; Korean Multiple Myeloma Working Party. Bang SM, et al. Among authors: yoon ss, yoon hj. Int J Hematol. 2006 May;83(4):309-13. doi: 10.1532/IJH97.A30512. Int J Hematol. 2006. PMID: 16757429

3

Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.

Koh Y, Park J, Ahn KS, Kim I, Bang SM, Lee JH, Yoon SS, Soon Lee D, Yiul Lee Y, Park S, Kim BK. Koh Y, et al. Among authors: yoon ss. Ann Hematol. 2009 Nov;88(11):1089-97. doi: 10.1007/s00277-009-0733-7. Epub 2009 Mar 19. Ann Hematol. 2009. PMID: 19296110

4

Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype.

Koh Y, Park J, Bae EK, Ahn KS, Kim I, Bang SM, Lee JH, Yoon SS, Lee DS, Lee YY, Park S, Kim BK. Koh Y, et al. Among authors: yoon ss. Int J Hematol. 2009 Jul;90(1):1-5. doi: 10.1007/s12185-009-0350-1. Epub 2009 May 30. Int J Hematol. 2009. PMID: 19484332

5

Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide.

Koh Y, Bang SM, Lee JH, Yoon HJ, Do YR, Ryoo HM, Lee N, Kim SJ, Kim K, Yoon SS, Won JH, Mun YC, Lee MH, Rhee KH, Kim HJ, Eom H, Kim MK, Shin HC; Korean Multiple Myeloma Working Party. Koh Y, et al. Among authors: yoon ss, yoon hj. Ann Hematol. 2010 Feb;89(2):201-6. doi: 10.1007/s00277-009-0807-6. Epub 2009 Aug 25. Ann Hematol. 2010. PMID: 19705118

6

Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry.

Kim SJ, Kim K, Kim BS, Jo DY, Kang HJ, Kim JS, Mun YC, Kim CS, Sohn SK, Eom HS, Kwak JY, Shim H, Yoon HJ, Jin JY, Min CK, Shin H, Won JH, Lee JJ, Kwon JH, Joo YD, Do YR, Kim SH, Oh S, Suh C, Lee J, Yoon SS, Kim MK, Bang SM, Ryoo HM, Kim BS, Kim H, Kim HJ, Kim YS, Park CW, Lee GW, Shin HJ, Park SK, Park JS, Kim HY, Lee DS, Lee JH; Korean Multiple Myeloma Working Party. Kim SJ, et al. Among authors: yoon ss, yoon hj. Acta Haematol. 2009;122(4):200-10. doi: 10.1159/000253027. Epub 2009 Oct 29. Acta Haematol. 2009. PMID: 19887776

7

Hypoplastic myelodysplastic syndrome (h-MDS) is a distinctive clinical entity with poorer prognosis and frequent karyotypic and FISH abnormalities compared to aplastic anemia (AA).

Koh Y, Lee HR, Song EY, Kim HK, Kim I, Park S, Park MH, Kim BK, Yoon SS, Lee DS. Koh Y, et al. Among authors: yoon ss. Leuk Res. 2010 Oct;34(10):1344-50. doi: 10.1016/j.leukres.2010.03.001. Epub 2010 Apr 27. Leuk Res. 2010. PMID: 20427085

8

Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.

Park J, Kim KI, Koh Y, Won NH, Oh JM, Lee DS, Kim BK, Ahn KS, Yoon SS. Park J, et al. Among authors: yoon ss. Exp Hematol. 2010 Sep;38(9):773-81. doi: 10.1016/j.exphem.2010.04.012. Epub 2010 May 21. Exp Hematol. 2010. PMID: 20438801

9

Clinical course of non-severe aplastic anemia in adults.

Kwon JH, Kim I, Lee YG, Koh Y, Park HC, Song EY, Kim HK, Yoon SS, Lee DS, Park SS, Shin HY, Park S, Park MH, Ahn HS, Kim BK. Kwon JH, et al. Among authors: yoon ss. Int J Hematol. 2010 Jun;91(5):770-5. doi: 10.1007/s12185-010-0601-1. Epub 2010 Jun 5. Int J Hematol. 2010. PMID: 20524094

10

Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8.

Koh Y, Kim I, Bae JY, Song EY, Kim HK, Yoon SS, Lee DS, Park SS, Park MH, Park S, Kim BK. Koh Y, et al. Among authors: yoon ss. Jpn J Clin Oncol. 2010 Nov;40(11):1037-45. doi: 10.1093/jjco/hyq097. Epub 2010 Jun 29. Jpn J Clin Oncol. 2010. PMID: 20587614

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,230 results

Search Page

Filters